Innoviva Inc (INVA) — closed signal from March 16, 2026
Partial Published before the outcome was known, scored automatically when the window closed on June 14, 2026 — +2.3% at the close.
Predicted vs. what happened
What happened
Reached 71% of the predicted growth at its peak, without hitting the target.
The thesis — published March 16, 2026
Recent company news makes the business story broader and more commercial, and management added a buyback while outlining a clearer list of upcoming events that could push the stock higher. Valuation and cash give some downside protection, and the shares look recovered from prior weakness. However, low trading volume can make short-term moves unreliable, so treat this as an interesting short-term watch idea rather than a high-conviction buy.
Primary drivers
- Buyback and upcoming events could help the stock recover
- Moving toward specialty-commercial products expands growth opportunities
- Cash and valuation provide some protection on downside
- Low trading volume can make short-term price moves unstable
How it played out
INVA: rose 10% but missed the target
Lyra published a short-term thesis that expected a 14% rise from $22.22 to $25.33. The thesis pointed to the buyback, upcoming events, a broader specialty-commercial business, and support from cash and valuation. It also flagged low trading volume as a source of unstable price moves.
INVA peaked at $24.45 on April 20, a 10% gain, but never reached the target. The shares ended the window at $22.74. The expected rise partially played out, but the published target was missed.
What happened during the window
On May 6, Innoviva reported first-quarter revenue of $98.0 million and said it had repurchased 971,066 shares for $20.4 million during the quarter. On June 1, the company announced management's participation in two June investor conferences.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.